IS4902A - Stilliefni fyrir endurmyndun vefja - Google Patents

Stilliefni fyrir endurmyndun vefja

Info

Publication number
IS4902A
IS4902A IS4902A IS4902A IS4902A IS 4902 A IS4902 A IS 4902A IS 4902 A IS4902 A IS 4902A IS 4902 A IS4902 A IS 4902A IS 4902 A IS4902 A IS 4902A
Authority
IS
Iceland
Prior art keywords
adjuster
tissue regeneration
purified
new
nucleic acid
Prior art date
Application number
IS4902A
Other languages
English (en)
Other versions
IS2636B (is
Inventor
Sanicola-Nadel Michele
V. Bonventre Joseph
A. Hession Catherine
Ichimura Takaharu
Wei Henry
L. Cate Richard
Original Assignee
Biogen Idec Ma Inc.
The Genaral Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26690881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS4902(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Ma Inc., The Genaral Hospital Corporation filed Critical Biogen Idec Ma Inc.
Publication of IS4902A publication Critical patent/IS4902A/is
Publication of IS2636B publication Critical patent/IS2636B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)
IS4902A 1996-05-24 1998-11-20 Stilliefni fyrir endurmyndun vefja IS2636B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1822896P 1996-05-24 1996-05-24
US2344296P 1996-08-23 1996-08-23
PCT/US1997/009303 WO1997044460A1 (en) 1996-05-24 1997-05-23 Modulators of tissue regeneration

Publications (2)

Publication Number Publication Date
IS4902A true IS4902A (is) 1998-11-20
IS2636B IS2636B (is) 2010-06-15

Family

ID=26690881

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4902A IS2636B (is) 1996-05-24 1998-11-20 Stilliefni fyrir endurmyndun vefja

Country Status (26)

Country Link
US (4) US6664385B1 (is)
EP (2) EP1655367A1 (is)
JP (3) JP4602482B2 (is)
CN (1) CN1147584C (is)
AT (1) ATE318903T1 (is)
AU (1) AU712289B2 (is)
BG (1) BG64678B1 (is)
BR (1) BR9709115A (is)
CA (1) CA2257851C (is)
CZ (1) CZ295936B6 (is)
DE (1) DE69735364T3 (is)
DK (1) DK0907735T5 (is)
EA (1) EA004402B1 (is)
EE (1) EE04817B1 (is)
ES (1) ES2258793T5 (is)
HU (1) HU226205B1 (is)
IL (1) IL127162A (is)
IS (1) IS2636B (is)
NO (2) NO327597B1 (is)
NZ (1) NZ336467A (is)
PL (1) PL188826B1 (is)
PT (1) PT907735E (is)
SI (1) SI0907735T2 (is)
SK (1) SK285461B6 (is)
TR (1) TR199802421T2 (is)
WO (1) WO1997044460A1 (is)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4602482B2 (ja) * 1996-05-24 2010-12-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組織再生のモジュレーター
EP0983357A1 (en) * 1997-05-23 2000-03-08 Biogen, Inc. Modulators of tissue regeneration
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CN101818145A (zh) 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1160321A1 (en) * 2000-05-31 2001-12-05 Sanofi-Synthelabo Kidney Injury Novel Gene-1: Isolation and therapeutic applications
JP2004500879A (ja) 2000-06-16 2004-01-15 バイオジェン　インコーポレイテッド 腎の調節エレメントおよびそれらの使用方法
US6812002B2 (en) * 2000-08-30 2004-11-02 Pfizer Inc. Osteoactivin protein and nucleic acids encoding the same, compositions and methods of stimulating bone differentiation
DK1401869T3 (da) 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
JP4572276B2 (ja) * 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
AU2003228336B2 (en) * 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2512138C (en) * 2002-12-30 2013-07-16 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
CA2519528C (en) * 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
CA2565701A1 (en) 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
RU2283666C9 (ru) * 2004-05-14 2007-03-10 Бизяев Алексей Вячеславович Средство для активации восстановления структуры и функции поврежденных тканей и органов
US20060003345A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc RNA bioassay
DK1831699T3 (da) * 2004-12-20 2010-03-15 Antibodyshop As Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme
EP1865985B1 (en) 2005-03-02 2010-08-25 Biogen Idec MA Inc. Kim-1 antibodies for treatment of th2-mediated conditions
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
EP1957115B8 (en) 2005-11-10 2014-03-05 Celldex Therapeutics, Inc. Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
PL2035835T3 (pl) 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
WO2008017306A1 (en) * 2006-08-07 2008-02-14 Antibodyshop A/S Diagnostic test to exclude significant renal injury
EP2137538B1 (en) * 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostic test for renal injury
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090297479A1 (en) * 2008-03-28 2009-12-03 Kiyoshi Ariizumi Dc-hil conjugates for treatment of t-cell disorders
JP2012501456A (ja) * 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
CA2735590A1 (en) * 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010048346A1 (en) 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2767833A3 (en) * 2008-10-21 2014-12-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104330574B (zh) 2008-11-10 2017-04-12 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
EP2364370B1 (en) * 2008-11-22 2014-09-03 Astute Medical, Inc. Methods for prognosis of acute renal failure
DK2391653T3 (en) * 2009-01-28 2015-02-09 Ind Tech Res Inst Biomarkers associated nephropathy
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20120061863A (ko) 2009-08-07 2012-06-13 아스튜트 메디컬 인코포레이티드 신장 손상 및 신부전증의 진단과 예후를 위한 방법 및 조성물
US20120264148A1 (en) 2009-08-07 2012-10-18 Dashurie Nezieri Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX340078B (es) 2009-11-07 2016-06-24 Astute Medical Inc Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal.
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
CN102791885B (zh) 2010-02-05 2015-09-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
EP2539712A4 (en) 2010-02-26 2013-09-18 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
IN2012MN02812A (is) 2010-06-23 2015-05-22 Astute Medical Inc
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN103491969A (zh) * 2011-02-09 2014-01-01 拉维沃公司 恢复和重建肠道微生物群的合生素组合物
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US10420337B2 (en) 2013-03-15 2019-09-24 Lifeline Scientific, Inc. Transporter with a glucose sensor for determining viability of an organ or tissue
US10265424B2 (en) * 2014-03-04 2019-04-23 Trust-Biosonics, Inc. Molecular imaging contrast agents and uses thereof
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
AU4116793A (en) * 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1995021922A2 (en) * 1994-02-14 1995-08-17 Abbott Laboratories Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use
US5622861A (en) * 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
EP0804547A4 (en) * 1994-08-18 1999-11-03 Univ Columbia UNIQUE SEQUENCES AND THEIR APPLICATIONS ASSOCIATED WITH CAPOSISAR COMAVIRUS
US6069230A (en) * 1994-11-10 2000-05-30 Promega Corporation High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
JP4602482B2 (ja) * 1996-05-24 2010-12-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組織再生のモジュレーター
JP2004500879A (ja) * 2000-06-16 2004-01-15 バイオジェン　インコーポレイテッド 腎の調節エレメントおよびそれらの使用方法
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
US7838220B2 (en) * 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
JP4572276B2 (ja) * 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
US7215871B2 (en) * 2001-07-27 2007-05-08 Thomson Licensing Changing a playback speed for video presentation recorded in a field structure format
US7687454B2 (en) * 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
JP4694128B2 (ja) * 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
AU2003228336B2 (en) * 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2512138C (en) * 2002-12-30 2013-07-16 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
BRPI0509139A (pt) * 2004-03-24 2007-08-28 Telos Fharmaceuticals Inc composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor

Also Published As

Publication number Publication date
BG64678B1 (bg) 2005-11-30
US20060286031A1 (en) 2006-12-21
DE69735364D1 (de) 2006-04-27
SI0907735T2 (sl) 2010-01-29
TR199802421T2 (xx) 1999-02-22
JP2008067701A (ja) 2008-03-27
US20070141590A1 (en) 2007-06-21
NZ336467A (en) 2000-10-27
JP4602482B2 (ja) 2010-12-22
EA199801044A1 (ru) 1999-04-29
PL188826B1 (pl) 2005-04-29
NO985427D0 (no) 1998-11-20
CA2257851A1 (en) 1997-11-27
NO20090945L (no) 1999-01-25
DK0907735T3 (da) 2006-06-26
SK285461B6 (sk) 2007-02-01
EE9800409A (et) 1999-06-15
US20050089868A1 (en) 2005-04-28
EP0907735B2 (en) 2009-10-07
NO985427L (no) 1999-01-25
NO327597B1 (no) 2009-08-31
ES2258793T5 (es) 2010-01-25
EP0907735B1 (en) 2006-03-01
CN1147584C (zh) 2004-04-28
IL127162A0 (en) 1999-09-22
DK0907735T4 (da) 2009-12-21
BG102967A (bg) 2000-05-31
EP0907735A1 (en) 1999-04-14
EA004402B1 (ru) 2004-04-29
DK0907735T5 (da) 2010-06-14
HK1021746A1 (en) 2000-06-30
EE04817B1 (et) 2007-04-16
PT907735E (pt) 2006-06-30
CN1223685A (zh) 1999-07-21
WO1997044460A1 (en) 1997-11-27
AU3567697A (en) 1997-12-09
SI0907735T1 (sl) 2006-08-31
CA2257851C (en) 2011-11-15
PL330313A1 (en) 1999-05-10
HU226205B1 (en) 2008-06-30
CZ381398A3 (cs) 1999-05-12
ES2258793T3 (es) 2006-09-01
ATE318903T1 (de) 2006-03-15
HUP9902770A3 (en) 2001-09-28
JP2001505761A (ja) 2001-05-08
EP1655367A1 (en) 2006-05-10
CZ295936B6 (cs) 2005-12-14
HUP9902770A2 (hu) 1999-12-28
BR9709115A (pt) 1999-08-03
JP4316640B2 (ja) 2009-08-19
DE69735364T2 (de) 2006-11-30
SK160998A3 (en) 1999-07-12
US6664385B1 (en) 2003-12-16
EP0907735B9 (en) 2010-05-19
IS2636B (is) 2010-06-15
JP2009039111A (ja) 2009-02-26
DE69735364T3 (de) 2010-05-06
IL127162A (en) 2007-07-24
AU712289B2 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
IS2636B (is) Stilliefni fyrir endurmyndun vefja
ATE328896T1 (de) Faktor viii vom schwein und hybriden
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
FI951612A7 (fi) Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sis ältävät nukleotidien välisiä ei-fosfodiesterisidoksia
DE69707849D1 (de) Verfahren zur reinigung von 1,4-butandiol
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
HUT77049A (hu) Katepszin-02-fehérjék, -nukleinsavak és -ellenanyagok
ATE179986T1 (de) Verfahren zur herstellung von 1-(2'-deoxy-2',2'- difluoro-d-ribofuranosyl)-4-amino-pyrimidin-2-o - hydrochlorid
HRP20010036B1 (hr) Neurotrofni faktor rasta
DE69527803D1 (de) Aufgereinigte dna-polymerase von thermococcus barossii
FI962087L (fi) Olefiinien polymerointiin tarkoitettu stereospesifinen katalyyttisysteemi ja monivaiheiset polymerointiprosessit, joissa tätä systeemiä käytetään
WO1997023611A3 (de) Nukleinsäuresequenzen von genen der high mobility group proteine sowie verwendungen derselben
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
EP0749312A4 (en) DIROFILARIA IMMITIS - Gp29 - PROTEINS, NUCLEIC ACID MOLECULES AND THEIR USE
PE20399A1 (es) Muteina ob
FR2698102B1 (fr) Composition destinée au lavage de la peau ou des muqueuses.
ITTO940070V0 (it) Filtro aria con supporto in poliuterano, particolarmente per l'abita- colo di autoveicoli.
DE69414375D1 (de) Verfahren zur herstellung von 1,1,1,2,2-pentafluoroethan, verfahren zur herstellung von 2,2-dichloro-1,1,1-trifluoroethan und verfahren zur reinigung von 1,1,1,2,2-pentafluoroethan
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
DE69607582D1 (de) Verfahren zur Herstellung und Reinigung von 1,1,1-Tris(4-hydroxyphenyl)ethan
ATE237572T1 (de) Verfahren zur reiningung von 1,3,5- triisopropylbenzol
DE59708626D1 (de) Verfahren zur herstellung von 4,5,6-trichlor- und 2,4,5,6-tetrachlorpyrimidin